Skip to contentG
GeneDx Holdings Corp.
G
WGSGeneDx Holdings Corp. Q2 2024 · 10-Q
Revenue$70.51M$70.51M+44.8% vs Q2 2023 Net Income-$29.17M-$29.17MN/M vs Q2 2023 EPS Diluted-$1.10-$1.10N/M vs Q2 2023 Gross Profit$42,952,000+129.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GeneDx Holdings Corp. · CIK 1818331 · Engraved from SEC EDGAR
Operating Cash Flowderived-$4,505,000N/M Free Cash Flowderived-$5,857,000N/M Margins · derivedGross margin60.9%+22.4 pt vs Q2 2023
Operating margin-15.0%+91.0 pt vs Q2 2023
Net margin-41.4%+54.5 pt vs Q2 2023
ended Jun 30, 2024 · filed Jul 30, 2024 · 30 d after period end